Literature DB >> 23932206

Impact of low-density lipoprotein cholesterol on cardiovascular outcomes in people with type 2 diabetes: a meta-analysis of prospective cohort studies.

Yujie Wang1, Carol J Lammi-Keefe, Lifang Hou, Gang Hu.   

Abstract

AIMS: To estimate the prospective association of low-density lipoprotein (LDL) cholesterol on cardiovascular disease (CVD) risk among people with type 2 diabetes.
METHODS: We used extensive literature searching strategies to locate prospective cohort studies that reported LDL cholesterol levels as a risk factor for cardiovascular events. We conducted meta-analytic procedures for two outcomes: incident CVD and CVD mortality.
RESULTS: A total of 16 studies were included in this analysis with a mean follow-up range of 4.8-11 years. The pooled relative risk associated with a 1mmol/L increase in LDL cholesterol in people with type 2 diabetes was 1.30 (95% confidence interval [CI], 1.19-1.43) for incident CVD, and 1.50 (95% CI, 1.25-1.80) for CVD mortality, respectively. Subgroup analyses showed that for incident CVD, the pooled relative risk was 1.28 (95% CI, 1.17-1.41) for 7 studies adjusted for blood pressure and/or glucose concentration (or insulin concentration, glycated hemoglobin) and 1.40 (95% CI, 1.05-1.86) for 3 studies that did not adjust for these variables.
CONCLUSIONS: Our study demonstrates that LDL cholesterol was associated with an increased risk for cardiovascular outcomes in people with type 2 diabetes, independent of other conventional risk factor.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cardiovascular outcomes; Low-density lipoprotein cholesterol; Meta-analysis; Type 2 diabetes

Mesh:

Substances:

Year:  2013        PMID: 23932206      PMCID: PMC4141536          DOI: 10.1016/j.diabres.2013.07.009

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  48 in total

1.  Global healthcare expenditure on diabetes for 2010 and 2030.

Authors:  Ping Zhang; Xinzhi Zhang; Jonathan Brown; Dorte Vistisen; Richard Sicree; Jonathan Shaw; Gregory Nichols
Journal:  Diabetes Res Clin Pract       Date:  2010-02-19       Impact factor: 5.602

2.  Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.

Authors:  M A Austin; M C King; K M Vranizan; R M Krauss
Journal:  Circulation       Date:  1990-08       Impact factor: 29.690

3.  Standards of medical care in diabetes--2013.

Authors: 
Journal:  Diabetes Care       Date:  2013-01       Impact factor: 19.112

4.  Joint role of non-HDL cholesterol and glycated haemoglobin in predicting future coronary heart disease events among women with type 2 diabetes.

Authors:  M B Schulze; I Shai; J E Manson; T Li; N Rifai; R Jiang; F B Hu
Journal:  Diabetologia       Date:  2004-12-15       Impact factor: 10.122

5.  Atherogenic concentrations of native low-density lipoproteins down-regulate nitric-oxide-synthase mRNA and protein levels in endothelial cells.

Authors:  F Vidal; C Colomé; J Martínez-González; L Badimon
Journal:  Eur J Biochem       Date:  1998-03-15

Review 6.  Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials.

Authors:  João Costa; Margarida Borges; Cláudio David; António Vaz Carneiro
Journal:  BMJ       Date:  2006-04-03

7.  Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus.

Authors:  Elizabeth Selvin; Spyridon Marinopoulos; Gail Berkenblit; Tejal Rami; Frederick L Brancati; Neil R Powe; Sherita Hill Golden
Journal:  Ann Intern Med       Date:  2004-09-21       Impact factor: 25.391

8.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.

Authors:  N Sarwar; P Gao; S R Kondapally Seshasai; R Gobin; S Kaptoge; E Di Angelantonio; E Ingelsson; D A Lawlor; E Selvin; M Stampfer; C D A Stehouwer; S Lewington; L Pennells; A Thompson; N Sattar; I R White; K K Ray; J Danesh
Journal:  Lancet       Date:  2010-06-26       Impact factor: 202.731

9.  Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes.

Authors:  Rui Jiang; Matthias B Schulze; Tricia Li; Nader Rifai; Meir J Stampfer; Eric B Rimm; Frank B Hu
Journal:  Diabetes Care       Date:  2004-08       Impact factor: 19.112

10.  Cause-specific mortality in a population-based study of diabetes.

Authors:  S E Moss; R Klein; B E Klein
Journal:  Am J Public Health       Date:  1991-09       Impact factor: 9.308

View more
  13 in total

Review 1.  Japanese Clinical Practice Guideline for Diabetes 2016.

Authors:  Masakazu Haneda; Mitsuhiko Noda; Hideki Origasa; Hiroshi Noto; Daisuke Yabe; Yukihiro Fujita; Atsushi Goto; Tatsuya Kondo; Eiichi Araki
Journal:  Diabetol Int       Date:  2018-03-27

Review 2.  Japanese Clinical Practice Guideline for Diabetes 2019.

Authors:  Eiichi Araki; Atsushi Goto; Tatsuya Kondo; Mitsuhiko Noda; Hiroshi Noto; Hideki Origasa; Haruhiko Osawa; Akihiko Taguchi; Yukio Tanizawa; Kazuyuki Tobe; Narihito Yoshioka
Journal:  Diabetol Int       Date:  2020-07-24

3.  Impact of different dietary approaches on blood lipid control in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.

Authors:  Manuela Neuenschwander; Georg Hoffmann; Lukas Schwingshackl; Sabrina Schlesinger
Journal:  Eur J Epidemiol       Date:  2019-06-14       Impact factor: 8.082

Review 4.  Diabetes complications and extracellular vesicle therapy.

Authors:  Setareh Soltani; Kamran Mansouri; Shahram Parvaneh; Avnesh S Thakor; Flemming Pociot; Reza Yarani
Journal:  Rev Endocr Metab Disord       Date:  2021-10-14       Impact factor: 6.514

5.  Japanese Clinical Practice Guideline for Diabetes 2019.

Authors:  Eiichi Araki; Atsushi Goto; Tatsuya Kondo; Mitsuhiko Noda; Hiroshi Noto; Hideki Origasa; Haruhiko Osawa; Akihiko Taguchi; Yukio Tanizawa; Kazuyuki Tobe; Narihito Yoshioka
Journal:  J Diabetes Investig       Date:  2020-07       Impact factor: 4.232

6.  Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies.

Authors:  Michel P Hermans; Evariste Bouenizabila; Daniel K Amoussou-Guenou; Sylvie A Ahn; Michel F Rousseau
Journal:  Cardiovasc Diabetol       Date:  2015-05-21       Impact factor: 9.951

7.  Japanese Clinical Practice Guideline for Diabetes 2016.

Authors:  Masakazu Haneda; Mitsuhiko Noda; Hideki Origasa; Hiroshi Noto; Daisuke Yabe; Yukihiro Fujita; Atsushi Goto; Tatsuya Kondo; Eiichi Araki
Journal:  J Diabetes Investig       Date:  2018-03-26       Impact factor: 4.232

8.  Association between ANGPTL3, 4, and 8 and lipid and glucose metabolism markers in patients with diabetes.

Authors:  Marina Harada; Tadashi Yamakawa; Rie Kashiwagi; Akeo Ohira; Mai Sugiyama; Yasuyuki Sugiura; Yoshinobu Kondo; Yasuo Terauchi
Journal:  PLoS One       Date:  2021-07-22       Impact factor: 3.240

9.  Mean platelet volume changes before and after glycated hemoglobin (HbA1c) improvement in a large study population.

Authors:  Yasar Sertbas; Meltem Sertbas; Nalan Okuroglu; Mehmet Akif Ozturk; Kerem Yigit Abacar; Ali Ozdemir
Journal:  Arch Med Sci       Date:  2016-08-22       Impact factor: 3.318

10.  Diabetes classification model based on boosting algorithms.

Authors:  Peihua Chen; Chuandi Pan
Journal:  BMC Bioinformatics       Date:  2018-03-27       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.